Introduction
The mechanism of action of Metformin has been studied for more than six decades, and it remains the most widely recommended first-line pharmacological therapy for Type 2 Diabetes Mellitus worldwide. (1) Its combination of efficacy, safety, affordability, and accessibility makes it the cornerstone of diabetes management in both public and private healthcare settings.
Despite its familiarity, metformin is frequently misused in clinical practice. Patients start on the wrong dose, the drug is continued in patients with contraindications, and important monitoring parameters are overlooked. These errors are preventable and understanding how metformin works is the first step.
This guide covers everything a clinician or healthcare student in Nigeria needs to know: the pharmacology, correct dosing strategy, drug interactions, adverse effects, monitoring requirements, and practical prescribing tips – all within the context of West African clinical practice.
Drug Class
Metformin belongs to the biguanide class of antidiabetic agents. It is an oral glucose-lowering drug that works independently of insulin secretion. Unlike sulphonylureas, metformin does not stimulate the pancreas to produce more insulin – which is why it does not cause hypoglycaemia when used as monotherapy. (2)
Indications
- Type 2 diabetes mellitus – first-line pharmacological therapy
- Polycystic ovary syndrome (PCOS) – widely used off-label in Nigeria for insulin resistance and ovulation induction
- Pre-diabetes and insulin resistance – to delay or prevent progression to type 2 diabetes
- Gestational diabetes mellitus – under specialist supervision
Dosage
Metformin dosing follows a start low, go slow principle. Rapid dose escalation is the most common cause of gastrointestinal side effects and the reason many patients abandon treatment unnecessarily.
| Phase | Dose | Frequency | Notes |
| Starting dose | 500 mg | Once daily with food | Week 1–2 |
| Dose escalation | 500 mg every 1–2 weeks | Increase gradually | As tolerated |
| Maintenance dose | 1,500 mg – 2,000 mg daily | 2–3 divided doses with meals | Most patients |
| Maximum dose | 3,000 mg daily | Divided doses | Rarely needed |
Always take metformin with or immediately after food to reduce gastrointestinal side effects. (3)
Mechanism of Action
Understanding the metformin mechanism of action helps explain both its benefits and its safety profile. Metformin works through three main pathways:
- Inhibits hepatic gluconeogenesis – Metformin activates AMP-activated protein kinase (AMPK) by inhibiting mitochondrial complex I. This reduces the liver’s production of glucose, which accounts for most of its glucose-lowering effect. (4)
- Improves peripheral insulin sensitivity – Enhances glucose uptake in skeletal muscle and adipose tissue, reducing post-meal glucose spikes.
- Reduces intestinal glucose absorption – Slows the rate at which carbohydrates are absorbed from the gastrointestinal tract, contributing to lower postprandial glucose levels.
The net result is lower fasting and postprandial blood glucose – without stimulating insulin and without causing hypoglycaemia as monotherapy.
Drug–Drug Interactions
Several drug interactions with metformin carry significant clinical risk. The following are the most important for clinicians in Nigeria to be aware of:
- Iodinated contrast media – Withhold metformin for 48 hours before and after administration of IV contrast agents. Co-administration in patients with renal impairment significantly increases the risk of lactic acidosis. (5)
- Alcohol – Potentiates the risk of lactic acidosis. Counsel patients to limit alcohol intake.
- Cimetidine – Inhibits renal tubular secretion of metformin, increasing plasma metformin concentrations. Monitor for toxicity.
- Corticosteroids – May antagonise the glucose-lowering effect of metformin by causing hyperglycaemia. Monitor blood glucose closely when initiating steroid therapy.
- Thiazide diuretics – Can worsen renal function, increasing the risk of metformin accumulation and lactic acidosis. Monitor eGFR.
- ACE inhibitors and ARBs – Commonly co-prescribed in Nigerian diabetic patients with hypertension. May reduce renal function – monitor eGFR at initiation and regularly thereafter.
Adverse Effects
Common Adverse Effects (Gastrointestinal)
These are dose-related and usually resolve with time or dose reduction:
- Nausea and vomiting
- Diarrhoea
- Abdominal discomfort and bloating
- Metallic taste in the mouth
Serious Adverse Effects
- Lactic acidosis – Rare but life-threatening. Risk is greatest in patients with renal impairment (eGFR <30 mL/min/1.73m²), liver disease, heart failure, or excessive alcohol use. Withhold metformin in any acute illness that could compromise renal perfusion. (5)
- Vitamin B12 deficiency – Long-term metformin use reduces ileal absorption of vitamin B12. Clinically significant deficiency has been reported in up to 30% of long-term users. Annual screening is recommended. (6)
Monitoring
Consistent monitoring is what separates safe prescribing from dangerous prescribing. The following parameters must be checked regularly in all patients on metformin:
| Parameter | When to Check | Action Threshold |
| Renal function (eGFR / creatinine) | Baseline, then annually (more often if at risk) | Reduce dose if eGFR 30–45. Stop if eGFR <30 |
| HbA1c | Every 3 months until stable, then every 6 months | Target <7% for most patients |
| Fasting blood glucose | As clinically indicated | Fasting target: 4.4–7.2 mmol/L |
| Vitamin B12 | Annually in patients on metformin >3 years | Supplement if low |
| Liver function tests | Baseline (caution in hepatic impairment) | Avoid in significant liver disease |
Clinical Tips
- Always titrate slowly. Most gastrointestinal side effects are caused by starting too high or escalating too fast. A slow titration significantly improves tolerability and patient adherence.
- Hold metformin in acute illness. Any condition that risks dehydration, sepsis, or haemodynamic instability – including severe vomiting, diarrhoea, or surgery – warrants temporary discontinuation.
- Stop before IV contrast procedures. Withhold 48 hours before and restart only when renal function is confirmed stable post-procedure.
- Metformin does not cause hypoglycaemia as monotherapy. Many patients and some clinicians are unnecessarily fearful. Reassure patients – this is one of metformin’s most important safety advantages.
- Consider extended-release (XR) if GI side effects persist. XR formulations significantly reduce gastrointestinal intolerance. Availability varies in Nigeria but is increasing.
- Check B12 in symptomatic patients. Peripheral neuropathy or unexplained anaemia in a long-term metformin user should prompt a B12 level check before attributing symptoms to diabetes alone.
Nigeria & West Africa Context
Type 2 diabetes prevalence in Nigeria is rising rapidly. The International Diabetes Federation estimates that Nigeria has one of the highest numbers of people living with diabetes in sub-Saharan Africa, with many cases undiagnosed. (7) Metformin remains the most prescribed antidiabetic drug in both primary and tertiary care settings across the country – yet several important clinical challenges persist:
- Renal function is inconsistently assessed before initiating metformin. Many patients in Nigerian primary care settings begin treatment without a baseline eGFR, meaning those with undiagnosed chronic kidney disease are at unrecognised risk of lactic acidosis.
- Vitamin B12 deficiency is underdiagnosed. Routine B12 monitoring is not yet standard practice in most Nigerian hospitals. Clinicians should maintain a high index of suspicion, particularly in elderly patients and those on long-term therapy.
- Herbal and traditional medicine interactions. A significant proportion of patients in Nigeria take traditional herbal preparations alongside prescribed medications without disclosing this to their clinicians. Some of these preparations may affect blood glucose and interact with metformin’s effects.
- Affordability and availability. Standard metformin tablets are widely available and affordable across Nigeria. Extended-release formulations are available in most urban pharmacies but may be harder to access in rural settings.
- Comorbid hypertension. The majority of Nigerian patients with type 2 diabetes also have hypertension, meaning ACE inhibitors or ARBs are frequently co-prescribed. Regular monitoring of renal function in this group is particularly important.
Conclusion
Metformin remains one of the safest, most effective, and most accessible antidiabetic drugs available to clinicians in Nigeria and across West Africa. Its metformin mechanism of action – primarily reducing hepatic glucose output – gives it a distinct and favourable pharmacological profile compared to other glucose-lowering agents.
Safe prescribing requires more than knowing the dose. It demands an understanding of the monitoring parameters, contraindications, and drug interactions that determine whether a patient benefits or is harmed. Whether you are initiating metformin in a newly diagnosed patient or reviewing a long-term user, the principles are consistent: titrate carefully, monitor regularly, and hold when in doubt.
As type 2 diabetes continues to rise across Nigeria and West Africa, getting metformin prescribing right is one of the most impactful clinical skills a healthcare professional can develop.
Need to check metformin drug interactions or verify a dose quickly at the point of care? Medituri’s Comprehensive Drug Database and Drug–Drug Interaction Checker give you instant, evidence-based clinical information – built specifically for healthcare professionals in Nigeria and West Africa. Visit medituri.com to explore the full platform.
References
- American Diabetes Association. Standards of Medical Care in Diabetes — 2023. Diabetes Care. 2023;46(Suppl 1):S1–S4.
- Bailey CJ, Turner RC. Metformin. New England Journal of Medicine. 1996;334(9):574–579.
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycaemia in Type 2 Diabetes: A Patient-Centred Approach. Diabetes Care. 2015;38(1):140–149.
- Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: From Mechanisms of Action to Therapies. Cell Metabolism. 2014;20(6):953–966.
- Lipska KJ, Bailey CJ, Inzucchi SE. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes Care. 2011;34(6):1431–1437.
- Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. Journal of Clinical Endocrinology & Metabolism. 2016;101(4):1754–1761.
International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels: IDF; 2021. Available from: https://www.diabetesatlas
